KUARTISMED MEDIKAL ARASTIRMA GELISTIRME DANISMANLIK EGITIM SANAYI VE TICARET LIMITED SIRKETI

Their core work

KuartisMED is a Turkish medical technology SME focused entirely on a single clinical problem: assessing feeding maturity in premature infants. Their core product — developed under the PREMADES project — is a measurement and evaluation system that helps neonatal clinicians determine when a preterm baby is ready to transition to oral feeding, a critical and often subjectively assessed milestone in neonatal intensive care. They successfully progressed from an EU-funded feasibility study (SME Instrument Phase 1) to a full commercial development grant (Phase 2), indicating a validated concept with a working prototype or early product. Their work sits at the intersection of neonatology, medical device development, and clinical measurement.

What they specialise in

How they've shifted over time

KuartisMED's trajectory is unusually linear: they entered H2020 in 2014 with a Phase 1 feasibility study on preterm feeding measurement and returned in 2017 with the same project at Phase 2 scale, suggesting a deliberate, focused commercialization path rather than diversification. There is no evidence of topic expansion or pivot — their entire EU-funded history is a single product line taken from concept to market. This focus is either a strength (deep specialization) or a limitation (single-product risk), and there are no signals of where they move next.

KuartisMED appears to be a single-product company in late-stage development of a neonatal feeding assessment device — potential future collaborations would most likely involve clinical validation studies, hospital pilots, or regulatory pathway support rather than new R&D.

How they like to work

KuartisMED has operated exclusively as a solo applicant through the SME Instrument, which does not require consortium partners — so their EU project history shows zero recorded collaborators. This suggests either a very self-contained development model or that external clinical and technical partners were engaged informally without appearing in CORDIS. Anyone considering a collaboration should expect to work with a small, founder-driven team that is used to owning the project rather than sharing leadership.

KuartisMED has no recorded EU consortium partners — both projects were executed as sole beneficiary under the SME Instrument scheme. Their formal European research network is effectively non-existent at this stage.

What sets them apart

KuartisMED appears to be one of very few Turkish SMEs in H2020 that built an entire product pipeline around preterm neonatal feeding assessment — a niche clinical need that receives little dedicated technology development globally. Their successful Phase 1-to-Phase 2 progression demonstrates that their concept survived EU expert evaluation twice, which is a meaningful quality signal in a competitive SME Instrument program. For a consortium needing a neonatal-focused technology provider or a clinical problem-holder in the Eastern Mediterranean market, they are a rare and specific fit.

Highlights from their portfolio

• PREMADES
  Rare example of a Turkish SME securing both Phase 1 (€50K) and Phase 2 (€1.456M) SME Instrument grants for the same product concept — a strong signal of validated commercial potential in neonatal care technology.